Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes
**Background:** Medical management of patients with type 2 diabetes mellitus (T2DM) is complex because of the chronic nature of the disease and its associated comorbidities. Injectable once-weekly semaglutide for diabetes (OW sema T2D) is a type of glucagon-like peptide–1 receptor agonist approved f...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-11-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.124111 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860367091040256 |
|---|---|
| author | Noelle N. Gronroos Caroline Swift Monica S. Frazer Andrew Sargent Michael Leszko Erin Buysman Sara Alvarez Tyler J. Dunn Josh Noone |
| author_facet | Noelle N. Gronroos Caroline Swift Monica S. Frazer Andrew Sargent Michael Leszko Erin Buysman Sara Alvarez Tyler J. Dunn Josh Noone |
| author_sort | Noelle N. Gronroos |
| collection | DOAJ |
| description | **Background:** Medical management of patients with type 2 diabetes mellitus (T2DM) is complex because of the chronic nature of the disease and its associated comorbidities. Injectable once-weekly semaglutide for diabetes (OW sema T2D) is a type of glucagon-like peptide–1 receptor agonist approved for the treatment of patients with T2DM.
**Objectives:** To describe patient characteristics and HbA1c changes for patients prescribed 1.0 mg maintenance dose OW sema T2D.
**Methods:** This retrospective study included adult patients with T2DM with a pre-index glycated hemoglobin (HbA1c) of at least 7%, initiating treatment with OW sema T2D between January 1, 2018, and December 31, 2019, and prescribed a 1.0 mg maintenance dose. Patients were identified in the Optum Research Database and were included if they had continuous health plan enrollment for at least 12 months prior to (pre-index) and at least 12 months following (post-index) the date of the first OW sema T2D claim (index). Dose at initiation and prescriber specialty were captured. Change in HbA1c between the latest post-index and pre-index HbA1c measurement was calculated among all patients and among those with at least 90 days of continuous treatment (persistent patients).
**Results:** A total of 2168 patients were included in this study. On average, patients were taking 13.5 different classes of medications. The majority of patients had lipid metabolism disorder (90.8%), hypertension (86.6%), diabetes with complications (86.8%), or other nutritional/endocrine/metabolic disorders (72.5%). The mean HbA1c reduction was 1.2% (P < .001). Patients persistent with OW sema T2D (n =1280) had a mean HbA1c reduction of 1.4% (P < .001). The mean (SD) days covered with a 1.0 mg maintenance dose was 236.1 (94.1) days.
**Discussion:** Despite being medically complex, the patients in this real-world study experienced significant reductions in HbA1c following initiation of OW sema T2D.
**Conclusions:** A 1.0 mg maintenance dose of OW sema T2D is an effective treatment for T2DM in the real world. |
| format | Article |
| id | doaj-art-b2929ceae31941f78603fc14f19f40a6 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-b2929ceae31941f78603fc14f19f40a62025-02-10T16:12:33ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362024-11-01112Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for DiabetesNoelle N. GronroosCaroline SwiftMonica S. FrazerAndrew SargentMichael LeszkoErin BuysmanSara AlvarezTyler J. DunnJosh Noone**Background:** Medical management of patients with type 2 diabetes mellitus (T2DM) is complex because of the chronic nature of the disease and its associated comorbidities. Injectable once-weekly semaglutide for diabetes (OW sema T2D) is a type of glucagon-like peptide–1 receptor agonist approved for the treatment of patients with T2DM. **Objectives:** To describe patient characteristics and HbA1c changes for patients prescribed 1.0 mg maintenance dose OW sema T2D. **Methods:** This retrospective study included adult patients with T2DM with a pre-index glycated hemoglobin (HbA1c) of at least 7%, initiating treatment with OW sema T2D between January 1, 2018, and December 31, 2019, and prescribed a 1.0 mg maintenance dose. Patients were identified in the Optum Research Database and were included if they had continuous health plan enrollment for at least 12 months prior to (pre-index) and at least 12 months following (post-index) the date of the first OW sema T2D claim (index). Dose at initiation and prescriber specialty were captured. Change in HbA1c between the latest post-index and pre-index HbA1c measurement was calculated among all patients and among those with at least 90 days of continuous treatment (persistent patients). **Results:** A total of 2168 patients were included in this study. On average, patients were taking 13.5 different classes of medications. The majority of patients had lipid metabolism disorder (90.8%), hypertension (86.6%), diabetes with complications (86.8%), or other nutritional/endocrine/metabolic disorders (72.5%). The mean HbA1c reduction was 1.2% (P < .001). Patients persistent with OW sema T2D (n =1280) had a mean HbA1c reduction of 1.4% (P < .001). The mean (SD) days covered with a 1.0 mg maintenance dose was 236.1 (94.1) days. **Discussion:** Despite being medically complex, the patients in this real-world study experienced significant reductions in HbA1c following initiation of OW sema T2D. **Conclusions:** A 1.0 mg maintenance dose of OW sema T2D is an effective treatment for T2DM in the real world.https://doi.org/10.36469/001c.124111 |
| spellingShingle | Noelle N. Gronroos Caroline Swift Monica S. Frazer Andrew Sargent Michael Leszko Erin Buysman Sara Alvarez Tyler J. Dunn Josh Noone Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes Journal of Health Economics and Outcomes Research |
| title | Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes |
| title_full | Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes |
| title_fullStr | Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes |
| title_full_unstemmed | Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes |
| title_short | Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes |
| title_sort | real world hba1c changes among type 2 diabetes mellitus patients initiating treatment with a 1 0 mg weekly dose of semaglutide for diabetes |
| url | https://doi.org/10.36469/001c.124111 |
| work_keys_str_mv | AT noellengronroos realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT carolineswift realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT monicasfrazer realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT andrewsargent realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT michaelleszko realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT erinbuysman realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT saraalvarez realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT tylerjdunn realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes AT joshnoone realworldhba1cchangesamongtype2diabetesmellituspatientsinitiatingtreatmentwitha10mgweeklydoseofsemaglutidefordiabetes |